Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK - PubMed
5 hours ago
- #CAR T-cell therapy
- #real-world outcomes
- #large B-cell lymphoma
- Axicabtagene ciloleucel (axi-cel) was approved as a second-line treatment for large B-cell lymphoma (LBCL) in the UK.
- Real-world outcomes showed 87.5% of approved patients (302 out of 345) received the treatment, with a median age of 62.
- The best overall response rate was 86%, with 64% achieving complete response.
- 12-month overall survival (OS) was 73.9% for treated patients, but only 1.5 months for those who did not proceed with CAR T.
- 12-month progression-free survival (PFS) was 52.4%, with factors like advanced stage, male sex, and high LDH/CRP affecting outcomes.
- Grade ≥3 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) rates were 5% and 18%, respectively.
- Outcomes in patients aged ≥70 were comparable to younger patients, supporting CAR T use in older fit individuals.
- The study confirms efficacy and safety similar to the ZUMA-7 trial, despite 42% requiring urgent holding therapy.